Compare compounds

Pick up to 3 compounds to see protocols, mechanisms, study endpoints and safety findings side by side.

KPV

Same goal

Include when printing

Only affects the printed page / PDF. The research-use-only notice always prints.

Protocol01

KPV

Tissue Repair

Vials · 10 mg

01Protocol

Vials: 10 mg
Dosing data: Lab reference — not listed

02Quick calculator

03Mechanism of action

KPV (Lys-Pro-Val) is the C-terminal tripeptide of α-MSH. It is taken up by the PepT1 transporter in gut and immune cells and inhibits NF-κB and MAP kinase inflammatory signalling.

04Study endpoints

In mouse colitis models, oral KPV reduced intestinal inflammation and pro-inflammatory cytokine expression.
An engineered oral KPV conjugate reached 3.8-fold higher colon levels than free KPV in colitic mice and was also anti-inflammatory in acute lung injury.

05Safety & regulatory findings

Not approved by the FDA or EMA for any indication; research-grade material is not a medicine.
Evidence is from cell and mouse studies; no human trials are cited.

06Citations

2 references · view